```html

Zollinger‑Ellison Syndrome – Refractory Acid Hypersecretion

Overview

Zollinger‑Ellison syndrome (ZES) is a rare neuroendocrine disorder in which one or more gastrin‑producing tumors (gastrinomas) develop, most often in the pancreas or duodenum. These tumors secrete excessive amounts of gastrin, a hormone that stimulates the stomach’s parietal cells to produce acid. The resulting “refractory” (hard‑to‑control) acid hypersecretion leads to severe peptic ulcer disease, diarrhea, and malabsorption.

Although ZES can occur at any age, the median age at diagnosis is 45–55 years, and it is slightly more common in men than women (approximately 55 % male). The syndrome is estimated to affect 0.5–2 people per million worldwide, making it an orphan disease, but its prevalence is higher among patients with Multiple Endocrine Neoplasia type 1 (MEN‑1), where up to 25 % develop gastrinomas.

Sources: Mayo Clinic, CDC, NIH Rare Diseases Information Center.

Symptoms

The hallmark of ZES is acid‑related gastrointestinal damage, but patients may present with a broad spectrum of signs. Symptoms often appear earlier than the diagnosis because the acid hypersecretion is “refractory” to standard antacid therapy.

• Recurrent or refractory peptic ulcers: Ulcers can occur in the duodenum, jejunum, or even beyond the duodenum – an unusual pattern for typical ulcer disease.
• Upper abdominal (epigastric) pain: Typically burning, worsened by meals or fasting.
• Diarrhea: Occurs in 60‑80 % of patients; the high acid load inactivates pancreatic enzymes, leading to fat malabsorption.
• Steatorrhea (fatty stools): Resulting from malabsorption; may cause weight loss.
• Frequent heartburn or gastro‑esophageal reflux disease (GERD):** Due to abundant acid reaching the esophagus.
• Nausea and vomiting: Often related to ulcer complications or gastric outlet obstruction.
• Gastrointestinal bleeding: Melena or hematemesis from ulcer erosion.
• Weight loss: Secondary to malabsorption, chronic diarrhea, and decreased oral intake because of pain.
• Fatigue and anemia: Chronic bleeding and malabsorption of iron/B12.
• Symptoms of associated MEN‑1: Hyperparathyroidism (bones, stones, groans) or pituitary adenomas may coexist.

Causes and Risk Factors

Primary cause – Gastrinomas

Most ZES cases are caused by sporadic gastrinomas (≈70 %). The remaining 30 % are part of MEN‑1, an autosomal‑dominant syndrome caused by mutations in the MEN1 tumor suppressor gene.

Risk factors

• Genetic predisposition: Having a first‑degree relative with MEN‑1 or a known MEN1 mutation markedly increases risk.
• Age: Though sporadic gastrinomas can appear at any age, incidence peaks between the fourth and sixth decades.
• Gender: Slight male predominance, but the difference is modest.
• Chronic atrophic gastritis or Helicobacter pylori infection: These conditions increase gastrin levels but rarely lead to ZES; they are more relevant for other hypergastrinemic states.

Diagnosis

Because the clinical picture overlaps with common ulcer disease, a high index of suspicion is essential, especially when ulcers are multiple, refractory, or located distal to the duodenum.

Biochemical tests

• Fasting serum gastrin: Levels > 1000 pg/mL (normal < 100 pg/mL) are strongly suggestive. However, elevated gastrin can also occur with proton‑pump inhibitor (PPI) therapy, renal failure, or atrophic gastritis; therefore, the test should be performed after 1–2 weeks off PPIs if feasible.
• Secretin stimulation test: Administering 0.4 U/kg IV secretin and measuring gastrin rise ≥ 120 pg/mL within 10 minutes is highly specific for gastrinoma.
• Chromogranin A: A tumor marker often elevated in neuroendocrine tumors; useful for follow‑up.

Imaging studies

• Somatostatin receptor scintigraphy (SRS) / Ga‑68 DOTATATE PET‑CT: The most sensitive modalities for locating gastrinomas, detecting tumors as small as 5 mm.
• CT or MRI of the abdomen: Helpful for defining size, local invasion, and metastatic spread, especially to the liver.
• EUS (Endoscopic Ultrasound): Excellent for detecting small (< 1 cm) pancreatic lesions.

Endoscopic evaluation

Upper endoscopy (EGD) documents ulcer location and severity, and biopsies exclude Helicobacter pylori or malignancy.

Diagnostic criteria (simplified)

1. Fasting gastrin > 1000 pg/mL (or > 10‑times upper limit) plus gastric acid hypersecretion; or
2. Positive secretin stimulation test.
3. Localization of a gastrinoma by imaging.

Treatment Options

Management aims to control acid hypersecretion, resect the tumor when possible, and monitor for recurrence or metastasis.

Acid suppression – first line

• High‑dose proton‑pump inhibitors (PPIs): Omeprazole 60–80 mg daily, esomeprazole 40–80 mg daily, or equivalent. PPIs are the most effective agents for controlling refractory acid production.
• Intravenous PPIs: In acute severe ulcer bleeding or in patients unable to take oral medications.
• H2‑receptor antagonists: May be added temporarily but are insufficient as monotherapy for ZES.

Acid control usually normalizes within 24–48 hours, allowing ulcer healing and symptom relief.

Surgical treatment

• Curative resection: Preferred when the gastrinoma is localized (< 2 cm) without metastasis. Options include pancreaticoduodenectomy (Whipple) for pancreatic head tumors or limited enucleation for duodenal lesions.
• Debulking surgery: Reduces tumor burden in metastatic disease to improve symptom control.
• Enucleation vs. formal resection: Determined by tumor size, location, and relationship to the pancreatic duct.

Medical therapies for unresectable or metastatic disease

• Somatostatin analogues (octreotide, lanreotide): Inhibit gastrin release and may arrest tumor growth.
• Targeted therapy (everolimus, sunitinib): Approved for progressive pancreatic neuroendocrine tumors.
• Chemotherapy: Generally reserved for high‑grade neuroendocrine carcinomas; limited role in typical gastrinomas.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE: Effective for somatostatin‑receptor positive metastases.

Lifestyle and supportive measures

• Avoid NSAIDs, aspirin, and other ulcerogenic drugs.
• Limit alcohol and caffeine, which stimulate acid secretion.
• Small, frequent meals may reduce gastric irritation.
• Supplement vitamin B12, iron, and fat‑soluble vitamins if malabsorption is evident.

Living with Zollinger‑Ellison Syndrome – Refractory Acid Hypersecretion

Even after successful treatment, patients often require lifelong management.

• Medication adherence: Take PPIs exactly as prescribed; missing doses can precipitate ulcer recurrence.
• Regular follow‑up: Serum gastrin and chromogranin A every 6–12 months, plus imaging as recommended by your oncologist.
• Monitor nutrition: Periodic assessment of weight, stool fat content, and laboratory markers (albumin, vitamins).
• Stress management: Chronic illness can increase anxiety; consider counseling or support groups.
• Vaccinations: If you receive biologic therapies (e.g., somatostatin analogues), stay up‑to‑date on flu, pneumococcal, and COVID‑19 vaccines.

Prevention

Because most cases are sporadic, primary prevention is limited. However, the following measures can reduce secondary risks:

• Early detection of MEN‑1 in families with a known MEN1 mutation through genetic counseling and screening.
• Avoid long‑term indiscriminate use of PPIs or H2 blockers without a clear indication; over‑suppression may mask early hypergastrinemia.
• Prompt treatment of H. pylori infection and avoidance of chronic NSAID use to reduce additional ulcer burden.

Complications

If left untreated or inadequately controlled, ZES can lead to serious health problems:

• Recurrent or perforated peptic ulcers: Can cause peritonitis and require emergency surgery.
• Upper gastrointestinal bleeding: Chronic blood loss → iron‑deficiency anemia.
• Gastrointestinal obstruction: From scarring or tumor growth.
• Malabsorption and nutritional deficiencies: Fat‑soluble vitamin (A, D, E, K) deficits, osteoporosis.
• Metastatic disease: Approximately 20‑30 % of sporadic gastrinomas metastasize, most often to the liver or regional lymph nodes.
• Bronchospasm or pulmonary complications: Rarely, acid aspiration can damage lungs.

When to Seek Emergency Care

---

References: Mayo Clinic, CDC Rare Diseases, NIH Rare Diseases Information Center, Cleveland Clinic, WHO Cancer Fact Sheets, Journal of Clinical Endocrinology & Metabolism (2022); Gastroenterology (2021).

```